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Abstract
Poor adherence to medical regimens can compromise the efficacy of treatments for children and
adolescents with juvenile rheumatoid arthritis (JRA). The purpose of this review is to describe
medical regimens for the treatment of JRA and the rates of adherence to these regimens. We also
summarize and critically the few research studies aimed at improving adherence to regimens for
JRA. Finally, we summarize strategies for enhancing adherence in clinical practice.
Background
Children and adolescents with juvenile rheumatoid
arthritis (JRA) are often asked to adhere consistently and
over a long period of time to a variety of medical regi-
mens, most notably, medications and therapeutic exer-
cises. We have chosen to use the term JRA because almost
all of the studies in this area have been done with children
meeting the American College of Rheumatology criteria
for JRA [1]. Regimens for JRA may have delayed beneficial
effects and in the short term may cause unwanted side-
effects such as gastrointestinal irritation and pain. This
constellation of factors associated with treatments for JRA
(i.e., the need for consistent adherence over a long period
of time, delayed beneficial effects, and negative side-
effects) are predictive of greater adherence problems to
medical regimens in pediatric chronic disease [2]. This
purpose of this review will be to 1) describe current regi-
mens, define adherence, and review the prevalence of
nonadherence to regimens for JRA; 2) summarize and crit-
ically evaluate research on improving adherence to regi-
mens for JRA; and 3) review strategies for enhancing
adherence in clinical practice.
Medical regimens for JRA
Pediatric rheumatic disease encompasses chronic multi-
system disorders that involve acute and chronic tissue
inflammation of the musculoskeletal system, blood ves-
sels, and skin. JRA is the most common form of chronic
arthritis and a major cause of both short and long-term
disability. Patients are often required to adhere to com-
plex medical regimens and cope with pain and psychoso-
cial aspects of their disease. The etiology of JRA is not
known but genetic and environmental factors likely are
important. The laboratory tests are rarely definitive, the
disease evolves over time and the treatment response is
often not predictable. Even with good disease control,
symptoms may fluctuate with other factors, such as inter-
current infection and weather changes.
Synovitis is the hallmark of the disease and there are three
basic subtypes, defined by the first 6 months of disease.
Systemic disease represents 10–15% of patients. These
patients have high fever, characteristic rash and usually
polyarticular arthritis, and may have organomegaly,
serositis and risk for macrophage activation syndrome.
Those children without major systemic symptoms are
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divided into polyarticular (≥ 5 joints) and pauciarticular
(≤ 4 joints) subtypes. Those children with polyarticular
disease usually have symmetric, small joint involvement,
particularly hands, wrists and hips. They often have low
grade symptoms or signs such as fatigue and anemia and
may be positive for rheumatoid factor, a marker for more
aggressive disease. Children with pauciarticular (oligoar-
ticular) disease are usually young, have predominantly
large joint involvement and a high risk for uveitis, anterior
chamber eye inflammation.
The general approach to treatment is a stepwise approach,
usually starting with non-steroidal anti-inflammatory
agents and aggressively adding additional drugs depend-
ing on therapeutic response. Other aspects of treatment
may need to address growth abnormalities (including
nutrition problems), vision, exercise needs-therapeutic
and general, school and social function, and psychosocial
and emotional health.
Defining adherence
"Adherence" is now the preferred term in the literature,
replacing the term "compliance". The term adherence bet-
ter reflects a more active role for patients in consenting to
and following prescribed treatments [2,3]. The World
Health Organization defines adherence as "the extent to
which a person's behavior – taking medication, following
a diet, and/or executing lifestyle changes, corresponds
with agreed recommendations from a health care pro-
vider" [4]. This definition acknowledges that regimens for
chronic conditions involve multiple behavioral compo-
nents, with varying levels of adherence to each compo-
nent, and that agreement to follow regimens has been
secured from the patient. In pediatric rheumatology,
agreement to follow prescribed regimens needs to be
obtained from caretakers as well as patients.
Another potentially useful distinction in the adherence lit-
erature is between inadvertent (non-volitional) and voli-
tional (or intentional) nonadherence [5]. Inadvertent
nonadherence may involve patients forgetting to take a
medication dose or being away from home without access
to medications. Whereas, volitional nonadherence may
involve a reasoned and purposeful decision by patients to
omit a medication dose, because they are asymptomatic,
taking medications that interferes with their lifestyle, or
are being defiant. In the case of inadvertent nonadher-
ence, one could help patients problem solve about how to
keep track of medication doses (such as using a pill
reminder case) and to have medications with them when
away from home. In the case of volitional nonadherence,
one would need to negotiate with patients and their fam-
ilies to obtain agreement on what they would be willing
to do to treat their disease without compromising their
quality of life.
Prevalence of nonadherence to regimens for JRA
There are few studies that have specifically addressed
adherence to regimens for JRA. Two retrospective studies
by Litt and her colleagues examined adherence to sali-
cylate medications in the treatment of JRA. In the first
study [6] adherence among 82 patients with JRA was
assessed using serum salicylate assays, with patients clas-
sified as adherent if their mean salicylate levels over a 19-
month period were above 20 mg/dl. Some 55% of adoles-
cents (n = 38) and 55% of children (n = 44) were found
to be adherent, In the second study [7], adherence among
38 adolescents with JRA was assessed using serum sali-
cylate assays obtained over a 12-month period, with
patients again classified as adherent if their salicylate lev-
els were greater than 20 mg/dl. Again, 55% of adolescents
were adherent.
In three separate within-subject design studies involving
five patients with JRA (ages 3 to 14 years), who were sus-
pected of having adherence problems by their pediatric
rheumatologist, our research group assessed baseline
adherence with salicylates and other medications, includ-
ing naproxen, penicillamine, prednisone, and tolmetin
sodium [8-10]. Adherence was assessed by parental obser-
vations or pill counts with independent interobserver reli-
ability assessments conducted by an investigator in the
patients' home or in the clinic (average interobserver
agreement exceeded 90%). Mean baseline adherence lev-
els with these medications among the five patients ranged
38% to 59%.
A recent study was unique in that it assessed adherence to
nonsteroidal antiinflammatory drugs (NSAIDs) among
48 newly-diagnosed children with JRA (mean age = 8.6
years) over 28 consecutive days using an electronic moni-
toring device [11]. For each participant, each day was
defined as being either "full adherence" (all prescribed
doses taken on time ± 2-hour forgiveness interval), "par-
tial adherence" (some but not all taken on time), and "no
adherence" (no doses taken at all). A "drug holiday" was
defined as two or more consecutive days with no doses
taken preceded and followed by at least one day with at
least partial adherence. Using median levels, patients
showed full adherence on 70% of the monitored days,
partial adherence on 14%, and no adherence on 7%.
There was considerable variability across patients, with
full adherence ranging from zero to 100% of the days. Sev-
enty-nine percent of patients took no drug holidays, 13%
took one, and the remaining 8% between two and four.
Using an 80% adherence cut point, 25 patients (52%)
were classified as adherent and 23 (48%) as nonadherent.
Patients with JRA are also asked to adhere to regimens
other than medications, such as therapeutic exercise and
wearing joint splints. Three studies have assessed parentalPediatric Rheumatology 2007, 5:10 http://www.ped-rheum.com/content/5/1/10
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and patient perceptions of adherence problems with these
types of regimens as well as medications. In the first study
[12], an adherence questionnaire was administered to 37
parents of children with JRA. The children were prescribed
medications and range-of-motion exercises, splints, or
both. Parents rated the degree of difficulty they have in
motivating their children to adhere to the different types
of regimens and noted any negative reactions their chil-
dren had to the regimens. Parents reported more prob-
lems with prescribed exercises as compared with
medications or splint wearing. Negative reactions to med-
ications were noted by 43% of parents, with the most
common reactions being complaining about taking med-
ications, forgetting to take them, and refusing to take
them. With reference to exercises, 60% of parents reported
that their children had negative reactions, with the most
frequent being complaining, refusing to do the exercises,
and crying. Also, 43% of parents reported that their chil-
dren had negative reactions to wearing splints; the most
common reactions were refusing to wear splints, ques-
tioning the efficacy of splints, and being embarrassed
about wearing splints at school or around friends. In the
second study [13], an adherence questionnaire was
administered to 93 parents of children with JRA and to 41
of the children with JRA. Adherence was also reported to
be lower for exercises as compared to medications. The
proportion of parents and children reporting adequate
adherence to medications (95% and 89%, respectively)
was significantly greater than the proportion of parents
and children who reported adequate adherence to exer-
cises (67% and 47%, respectively). In the third study [14],
fifty patients with juvenile idiopathic arthritis and their
parents completed questionnaires asking them about
adherence to medications, exercises, and splints. Specifi-
cally, they were asked about the frequency at which chil-
dren followed the treatments, difficulties in following the
treatments, any negative reactions to treatments, and the
degree to which the treatments actually helped. Both par-
ents and children rated adherence to medications as
higher than adherence to exercises (means of 84.9% and
83.1% for medications versus means of 61.2% and 57.4%
for exercises, for children and parents respectively). Com-
pared to their children, parents rated them as having more
difficulty doing exercises and as having more negative
reactions to take medications and doing exercises.
In the aggregate, these data suggest that the extent of
adherence to treatments for JRA can vary widely across dif-
ferent samples and methods of assessing adherence but
appears to be similar to what has been found with other
chronic pediatric diseases [2]. The three survey studies
would suggest that adherence to therapeutic exercises for
JRA is more problematic than adherence to medications.
What is not known is the optimal or minimal level of
adherence necessary to produce acceptable disease and
quality of life outcomes for patients. Clearly, there are
some patients with JRA who may benefit from efforts to
their enhance adherence. We now examine studies which
have attempted to enhance adherence to regimens for JRA.
Research on improving adherence to regimens for JRA
Two studies by our group have examined the efficacy of
parent-managed token reinforcement programs in alter-
ing adherence to regimens for JRA. These behavior modi-
fication programs involve awarding tokens (points or
poker chips) to children for adhering to regimen compo-
nents, taking away tokens for nonadherence, and allow-
ing children to purchase special or routine privileges with
tokens. The first study [8] focused on improving adher-
ence to medications, splint wearing, and prone lying (to
prevent hip contractures) for a 7-year-old female with
severe systemic-onset JRA. Adherence was assessed by
parental observations with acceptable interobserver relia-
bility (94%) obtained with an investigator conducting
independent observations in the home. A multiple-base-
line-across-behaviors design was employed to evaluate
the effects of the intervention on adherence. Mean base-
line adherence was low for medications (59%) and nil
(0%) for both splint wearing and prone lying. Introduc-
tion of the token system increased adherence to 95% for
medications, 77% for splint wearing, and 71% for prone
lying. At the 10-week follow-up (with the token system
withdrawn), adherence to medications, splint wearing,
and prone lying averaged 90%, 91%, and 80%, respec-
tively. Although not formally assessed, the pediatric rheu-
matologist anecdotally noted concomitant improvements
in function for this patient, such as greater hip extension.
The second study [9] also tested the efficacy of a token sys-
tem program in improving adherence to medications for
a 14-year-old male with polyarticular JRA. Adherence was
assessed by weekly pill counts obtained from the patient's
mother over the phone with independent counts by an
investigator in the clinic (agreement with the mother's
count was 100%). A withdrawal (reversal), single-subject
design was employed to evaluate the effects of the inter-
vention on adherence and several clinical outcome
parameters (e.g., active joint counts). Medication adher-
ence averaged 44% during baseline, increased to an aver-
age of 59% during a simplified regimen condition (when
the dosage was reduced from four to three times a day),
and further increased and remained at 100% during the
first token system phase. There was a decreasing trend in
adherence during a token system withdrawal phase (mean
= 77%), an increase during the second token system phase
(mean = 99%), and an average of 92% during the mainte-
nance phase (when the token system was not in effect but
could be reinstated if adherence dropped below 80% for
two consecutive weeks). At the nine-month follow-up (no
token system in effect and no contingency for reinstate-Pediatric Rheumatology 2007, 5:10 http://www.ped-rheum.com/content/5/1/10
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ment), adherence averaged 97%. Though not as straight-
forward as the adherence results, there were
improvements in clinical outcomes during the token sys-
tem and follow-up phases (e.g., 5 active joints) relative to
baseline and the token system withdrawal phase (e.g., 10
active joints).
Although the above-mentioned studies showed that token
systems could be effective in improving adherence, they
are labor-intensive for families and require well-trained
personnel to implement and monitor. Therefore, our
group reported on another study [10] that evaluated less
complex behavioral strategies (such as self-monitoring of
adherence by children and parents and positive verbal
feedback by parents for adherence) combined with educa-
tional strategies (verbal and written information about
medications for JRA, the importance of adherence, and
strategies for improving adherence). The study involved
three female patients with JRA, aged 3, 10, and 13 years
and adherence was assessed by weekly pill counts
obtained from parents over the phone with independent
counts by one of the investigators in the clinic (agreement
was 100%). A multiple baseline across subjects design was
used to evaluate the efficacy of the intervention. Baseline
medication adherence averaged 38% and 54% for two of
the patients and increased during the intervention phase
to an average of 97% and 92%, respectively. Adherence
only increased slightly for the third patient, from an aver-
age of 44% during baseline to an average of 49% during
the intervention phase. Adherence decreased for all three
patients at four-month follow-up (means ranged from
24% to 89%). Interestingly, the patient for whom the
intervention was least effective was a 13-year-old who had
less parental supervision of her regimen and whose
mother admitted she was nonadherent to medications
prescribed to treat her arthritis. Unfortunately, clinical
outcomes were not reported for these patients.
The above-mentioned studies suggest that adherence can
be improved by behavioral strategies alone or combined
with educational strategies, a combination that has
worked best for improving adherence to other chronic
pediatric diseases [2]. However, these studies involved
small sample sizes and did not generally assess clinical
outcomes, such as active joint counts. These studies also
involved patients who had been diagnosed with having
JRA for varying lengths of time and for whom nonadher-
ence was implicated as interfering with the effectiveness of
treatments by their pediatric rheumatologist. The success
of these interventions with limited numbers of patients
who were persistently nonadherent led our group to test
the possible benefits of intervening with newly diagnosed
patients in order to prevent the anticipated drop in adher-
ence over time which has been reported in the pediatric
adherence literature [2].
We conducted a randomized controlled trial evaluating a
clinic-based, nurse-administered educational and behav-
ioral intervention to promote adherence to nonsteroidal
medications among newly diagnosed patients with JRA
[15]. Thirty-four participants (mean age = 8.44 years)
were matched by age and type of JRA and then randomly
assigned to the experimental or (attention-placebo) con-
trol groups. Patients and parents in the experimental
group were given verbal, written, and audiovisual infor-
mation from a nurse about adherence improvement strat-
egies, including prompting, monitoring, positive
reinforcement, and discipline techniques [16]. Control
group patients and parents were given verbal, written, and
audiovisual information about JRA and treatments by the
same nurse, but no specific information about adherence
improvement strategies. Patients and parents in both
groups received their respective interventions during a 11/
2 hour clinic visit and were then telephoned by the nurse
biweekly for two months and then monthly for 10
months. The content of the phone calls centered on the
information presented during the initial clinic visit.
Adherence was assessed using the Medication Event Mon-
itoring System (MEMS; Aprex Corporation, Fremont, CA).
This electronic medication bottle cap records the date and
time of each bottle opening. It can store 1800 openings
and has an 18-month battery life. MEMS data are down-
loaded to a portable computer and analyzed with the
manufacturer's software, which provides daily and contin-
uous data on adherence (assuming that medications are
taken each time the pill cap is removed). The daily MEMS
adherence score was the percent of prescribed doses taken
within the recommended dosing interval, with a two-
hour (plus or minus) forgiveness interval (e.g., NSAID
twice daily, could be taken 10 to 14 hours between doses).
Disease activity and functional status measures were
obtained during routine clinic visits where the rheumatol-
ogist recorded standard clinical indices, including number
of active joints (those with pain, swelling, and limitation
of motion), the number of minutes of morning stiffness,
and a global disease activity rating (0 = off medication, in
remission, 1 = quiescent, 2 = mild, 3 = moderate, 4 =
severe). During these visits, the parents completed the
Childhood Health Assessment Questionnaire (CHAQ),
which is designed to assess disease-related functional lim-
itations over the past week in eight areas: dressing and
grooming, arising, eating, walking, hygiene, reach, grip,
and play. The eight scores are averaged to yield the CHAQ
Disability Index, ranging from 0 (no difficulty) to 3 (una-
ble to do).
For the 52-week post-intervention follow-up, the experi-
mental-group participants showed significantly better
overall average adherence than the controls (77.7% vs.
56.9%, p = .023) and as predicted, the trend in adherencePediatric Rheumatology 2007, 5:10 http://www.ped-rheum.com/content/5/1/10
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levels significantly dropped over time in the control group
but not in the experimental group. There were, however,
no significant post-intervention group differences on dis-
ease activity and functional status measures. The lack of
significant differences in disease-related outcomes may
have been due to "floor effects" (e.g., 68% of experimental
participants and 67% of controls had quiescent or mild
disease at baseline). This floor effect may have prevented
detection of improvements that could be unambiguously
attributed to the experimental adherence intervention.
A recent and unique randomized clinical trial focused on
preventing osteoporosis in children with JRA by increas-
ing calcium (Ca) intake [17]. Forty-nine children with JRA
(mean age 6 years) and their parents were randomly
assigned to a behavioral intervention (BI) group or an
enhanced standard of care (ESC) group. Children and par-
ents in the BI group met in separate groups for six sessions
and received nutritional counseling on how to increase
calcium intake and behavioral strategies (praise coupled
with use of a sticker chart to track progress for reaching tar-
geted calcium intake levels). Children and parent in the
ESC group were seen individually for 3 visits and received
nutritional counseling only. Three-day food diaries were
kept by parents at baseline and posttreatment and were
analyzed for calcium intake. Repeated measures analysis
demonstrated a significant group by time interaction with
children in the BI group achieving a greater increase in
dietary Ca intake from baseline to posttreatment com-
pared to the ESC group (p < .001). In addition, and of clin-
ical significance, 92% of children in the BI group achieved
the treatment goal of 1500 mg of Ca/day compared to
17% of children in the ESC group at posttreatment.
The above mentioned studies suggest that behavioral
strategies combined with education is the most effective
way to improve adherence to regimens for JRA and to pre-
vent deterioration in adherence over time in newly diag-
nosed patients. The one dietary study also suggests that
behavioral strategies are a necessary adjunct to nutritional
education in improving calcium intake for patients with
JRA. These findings are consistent with adherence inter-
vention studies for other chronic pediatric diseases such as
asthma, cystic fibrosis, and diabetes [2]. There are, how-
ever, too few adherence intervention studies and the ones
which have been published involve small sample sizes,
utilize less objective measures of adherence such as pill
counts, and often fail to demonstrate that improvements
in adherence produce improvements in disease and qual-
ity of life outcomes.
Enhancing adherence in clinical practice
By combining the results of pediatric rheumatology
adherence intervention studies with a larger database in
pediatric adherence research [2], strategies for enhancing
adherence can be recommended for clinical use. Studies
that have been done suggest a three-tiered approach to
minimize nonadherence: primary, secondary, and tertiary
prevention [18]. Primary prevention efforts would be most
relevant for those patients who have not yet exhibited
clinically significant nonadherence (inconsistencies in
following a particular regimen that may result in compro-
mised health and well-being); possibly those recently
diagnosed or those who are able to sustain adequate
adherence over time. Interventions at this level would
involve educational (e.g., stressing the importance of
adherence), organizational (e.g., simplifying regimens),
and relatively simple behavioral strategies (e.g., monitor-
ing of regimen adherence by providers or parents). Second-
ary prevention might be most applicable to those patients
for whom clinically significant nonadherence has been
identified early on in the disease course or has yet to com-
promise their health and well-being. Interventions at this
level might include more frequent monitoring of regimen
adherence by parents and patients, specific and consistent
positive social reinforcement for adherence, and general
discipline strategies (e.g., time-out for younger children).
Pediatric psychologists could train primary health care
providers, particularly nurses, to implement primary and
secondary level interventions. Tertiary prevention efforts
would apply to patients with an ongoing pattern of clini-
cally significant nonadherence. Strategies at this level
might include token system programs, contingency con-
tracting, self-management training (e.g., problem-solving
to anticipate and manage obstacles to adherence), and
possibly psychotherapy. Because of the demanding and
technical nature of these strategies, pediatric psychologists
would be responsible for implementing strategies at this
level.
Implementing and evaluating primary, secondary, and
tertiary prevention approaches to medical nonadherence
depends on a number of factors. First, prevention efforts
require a valid, reliable, and clinically feasible way to
detect or assess nonadherence. Although no such "ideal"
measure exists, 24-hour recall interviews (in clinics or by
phone) may be the best option in that they have been
shown to be reliable, valid, and feasible for routine and
serial assessments of adherence to regimens for diabetes
and cystic fibrosis and could be easily be adapted for JRA
regimens [2]. Second, information obtained from routine
and serial assessments of adherence should also allow for
the detection of clinically significant nonadherence. Previ-
ous attempts at determining levels of adherence necessary
to prevent deleterious health outcomes have been arbi-
trary and not biologically-based (e.g., adequate adherence
defined as consuming 80% of prescribed medication
doses). Third, because the desired outcome of adherence
interventions is that patients get better, feel better, and do
better, there is a need for both traditional (e.g., clinicalPediatric Rheumatology 2007, 5:10 http://www.ped-rheum.com/content/5/1/10
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signs and symptoms) and quality-of-life measures of dis-
ease and health status that are valid, reliable, and clini-
cally feasible [2]. In conjunction with disease and health
status measures, serial assessments of adherence would
help determine the optimal or minimal level of adherence
necessary to produce acceptable treatment outcomes.
Fourth, interventions must take into account the age and
developmental status of children. Interventions with
younger patients would necessarily involve extensive par-
ent involvement, while those with adolescents would
focus on engaging them in problem-solving and other
methods of enhancing their own adherence. Finally,
because JRA affects relatively small numbers of children
and adolescents, empirical validation of primary, second-
ary, and tertiary prevention interventions will require
multi-center collaborative research studies.
Improving adherence from a rheumatologists' viewpoint
Pediatric rheumatologists need to discuss adherence
issues with their patients. This is evident from one chart
review study that examined the medical records of 108
patients with JRA followed in a pediatric rheumatology
clinic over a 15 month period [19]. Of the 2,578 treat-
ment recommendations recorded in the charts, only
1,390 adherence-facilitating behaviors were documented,
with the most common one being that staff informed the
patient how often to perform treatments. The providers
rarely indicated that they addressed patients' concerns or
barriers relating to implementing treatments and they
rarely recommended behavior modification strategies.
Pediatric rheumatologists can keep abreast of the adher-
ence improvement literature but need practical advice on
how to improve adherence based on the best evidence
available and their own clinical experience. Table 1 pro-
vides just such a list of recommendations for enhancing
adherence in clinical practice. If these recommendations
are routinely implemented in clinical practice, most
adherence problems can be circumvented or addressed in
a timely fashion.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
Manuscript Preparation: Rapoff and Lindsley
Acknowledgements
This paper was based on a presentation given by the authors at the Amer-
ican College of Rheumatology/Association of Rheumatology Health Profes-
sionals Scientific Meeting, November 12, 2006, in Washington, D.C. Our 
research on adherence to regimens for pediatric rheumatic disease has 
been generously supported by Allied Health Professional Research Grants 
from the National Office of the Arthritis Foundation and from U.S. Public 
Health Service Grant MCJ-200617.
References
1. Brewer EJ, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, Hanson V, Lev-
inson JE, Schaller J, Stillman JS: Current proposed revision of JRA
criteria.  Arthritis Rheum 1977, 20:195-9.
2. Rapoff MA: Adherence to pediatric medical regimens.  New
York: Kluwer/Plenum; 1999. 
3. Lutfey KE, Wishner WJ: Beyond "compliance" if "adherence".
Diabetes Care 1999, 22:635-639.
4. World Health Organization: Adherence to long-term therapies:
Evidence for action.  Geneva, Switzerland 2003:3-4.
5. Adams CD, Dreyer ML, Dinakar C, Portnoy JM: Pediatric asthma:
A look at adherence from the patient and family perspective.
Curr Allergy Asthma Rep 2004, 4:425-432.
6. Litt IF, Cuskey WR: Compliance with salicylate therapy in ado-
lescents with juvenile rheumatoid arthritis.  Am J Dis Child 1981,
135:434-436.
7. Litt IF, Cuskey WR, Rosenberg A: Role of self-esteem and auton-
omy in determining medication compliance among adoles-
cents with juvenile rheumatoid arthritis.  Pediatrics 1982,
69:15-17.
8. Rapoff MA, Lindsley CB, Christophersen ER: Improving compli-
ance with medical regimens: Case study with juvenile rheu-
matoid arthritis.  Arch Phys Med Rehabil 1984, 65:267-269.
9. Rapoff MA, Purviance MR, Lindsley CB: Improving medication
compliance for juvenile rheumatoid arthritis and its effect on
clinical outcome: A single-subject analysis.  Arthritis Care Res
1988, 1:12-16.
10. Rapoff MA, Purviance MR, Lindsley CB: Educational and behavio-
ral strategies for improving medication compliance in juve-
nile rheumatoid arthritis.  Arch Phys Med Rehabil 1988,
69:439-441.
11. Rapoff MA, Belmont JM, Lindsley CB, Olson NY: Electronically
monitored adherence to medications by newly diagnosed
patients with juvenile rheumatoid arthritis.  Arthritis Care Res
2005, 53:905-910.
Table 1: 
Recommendations for Enhancing Adherence in Pediatric Rheumatology
1. Educate patients and families about the goals of treatment. Negotiate with them upfront about which treatments they are willing to try.
2. Make regimens as simple as possible and consistent with the patients' daily routine.
3. Educate patients and families about how to minimize treatment side effects and problem solve with them to address other barriers to adherence.
4. Ensure that patients and families have the requisite behavioral skills to implement regimens. Rehearse these in the clinic (e.g., demonstrate and 
have patients practice therapeutic exercises).
5. Encourage patients and caregivers to monitor adherence (e.g., use a calendar posted in a prominent place in the home).
6. Teach caregivers positive reinforcement strategies for promoting adherence (e.g., point system for adhering to regimen components).
7. Review discipline strategies with caregivers for children who are oppositional (e.g., time-out for younger child who refuses medications).
8. Teach older patients self-management strategies (e.g., problem-solving).
9. Refer patients and families to qualified mental health providers if more serious problems exist concurrently with nonadherence or are directly 
interfering with adherence.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Pediatric Rheumatology 2007, 5:10 http://www.ped-rheum.com/content/5/1/10
Page 7 of 7
(page number not for citation purposes)
12. Rapoff MA, Lindsley CB, Christophersen ER: Parent perceptions of
problems experienced by their children in complying with
treatments for juvenile rheumatoid arthritis.  Arch Phys Med
Rehabil 1985, 66:427-430.
13. Hayford JR, Ross CK: Medical compliance in Juvenile rheuma-
toid arthritis: problems and perspectives.  Arthritis Care Res
1988, 1:190-197.
14. April KT, Feldman DE, Platt RW, Duffy CM: Comparison between
children with juvenile idiopathic arthritis and their parents
concerning perceived treatment adherence.  Arthritis Rheum
2006, 55:558-563.
15. Rapoff MA, Belmont JM, Lindsley CB, Olson NY, Padur J: Prevention
of nonadherence to non-steroidal anti-inflammatory medi-
cations for newly diagnosed patients with juvenile rheuma-
toid arthritis.  Health Psychol 2002, 21:620-623.
16. Rapoff MA: Helping children follow their medical treatment
program: Guidelines for parents of children with rheumatic
diseases.  Available from the author, University of Kansas Medical Center,
Department of Pediatrics, 3901 Rainbow Blvd., Kansas City, KS 66160-
7330 1997.
17. Stark LJ, Janicke DM, McGrath AM, Mackner LM, Hommel KA, Lovell
D: Prevention of osteoporosis: A randomized clinical trial to
increase calcium intake in children with juvenile rheumatoid
arthritis.  J Pediatr Psychol 2005, 30:377-386.
18. Rapoff MA: Facilitating adherence to medical regimens for
pediatric rheumatic diseases: Primary, secondary, and terti-
ary prevention.  In Promoting adherence to medical treatment in
chronic childhood illness: Concepts, methods, and interventions Edited by:
Drotar D. Mahwah, NJ: Lawrence Erlbaum; 2000:329-345. 
19. Thompson SW, Dahlquist LM, Koenning GM, Bartholomew LK: Brief
report: Adherence-facilitating behaviors of a multidiscipli-
nary pediatric rheumatology staff.  J Pedatr Psychol 1995,
20:291-297.